BioSpace News Archive

Biotech Bay

4D Molecular Therapeutics to Participate in Upcoming June 2023 Investor Conferences

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced it will participate in the following upcoming investor conferences.

June 1, 2023
·
2 min read
Biotech Beach

Erasca to Present at Upcoming June 2023 Investor Conferences

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced that management will present at the investor conferences listed below.

June 1, 2023
·
1 min read
Business

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments

June 1, 2023
·
8 min read
Biotech Bay

Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company’s IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL , and virtually.

June 1, 2023
·
4 min read
Drug Development

Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy

Clarametyx Biosciences, Inc . today announced positive initial safety data from the Phase 1a portion of its clinical development program for CMTX-101, a novel immune-enabling antibody therapy designed to treat serious bacterial infections, with no safety concerns identified.

June 1, 2023
·
2 min read
Drug Development

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam.

June 1, 2023
·
11 min read
DiviTum(R) TKa Results to be Presented at ASCO

Biovica, active in cancer diagnostics, announces that a poster with DiviTum® TKa results from the SWOG study S0226 will be presented at the the world’s largest cancer conference, the annual ASCO meeting, on Sunday, June 4.

June 1, 2023
·
2 min read
Biotech Bay

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data

Akero Therapeutics, Inc. (Nasdaq: AKRO) will hold an investor conference on Monday, June 5 at 8:00 a.m. ET to share results from Cohort D of the Phase 2b SYMMETRY study.

June 1, 2023
·
5 min read
BioCapital

MaxCyte to Participate in Upcoming June 2023 Investor Conferences

MaxCyte, Inc. announced Company management will participate at the following investor conferences:

June 1, 2023
·
1 min read
Business

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the formation of a Scientific Advisory Board.

June 1, 2023
·
8 min read